I-MAB (IMAB) AI Stock Analysis

• Market Cap: $66.00M
• Dividend Yield: N/A
• Average Volume (3M): 244.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -0.71
• Shares Outstanding: 81,501,080
• 10 Day Avg. Volume: 226,187
• 30 Day Avg. Volume: 244,084
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 18.03
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.67
• Price Target Upside: 575.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

The overall stock score of 45 reflects I-MAB's substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

Positive Factors

Drug efficacy

Givastomig's differentiated safety profile and potential as a targeted treatment for Claudin 18.2-positive gastric and esophageal cancers is highlighted by its favorable pharmacokinetics and efficacy data.

Enrollment progress

Recent enrollment acceleration for giva is encouraging.

Financial stability

I-Mab ended with $173M in cash, providing runway into 2027.

Negative Factors

Clinical development decision

I-Mab is halting further clinical development of uliledlimab in NSCLC.

Pipeline valuation

Analyst is lowering the pipeline valuation from $350M to $200M.

Resource prioritization

I-Mab recently announced it will be prioritizing its remaining resources on givastomig, a CLDN18.2x4-1BB bispecific antibody.

I-MAB Business Overview & Revenue Model

Company Description

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

I-MAB primarily generates revenue through partnerships and collaborations with other pharmaceutical companies for the development and commercialization of its drug candidates. The company may receive upfront payments, milestone payments, and royalties from these partnerships as its drug candidates progress through clinical trials and reach the market. Additionally, I-MAB might gain revenue from licensing its proprietary technologies and intellectual property to other entities. Significant partnerships with global pharmaceutical companies facilitate the advancement of its pipeline, contributing to its earnings potential.

I-MAB Financial Statement Overview

Summary

I-MAB faces substantial financial challenges, particularly in terms of profitability and cash flow generation. Although the company benefits from a strong liquidity position and low leverage, its ability to generate positive earnings and cash flows remains a concern. The volatility in revenue and consistent losses highlight the need for strategic adjustments to improve financial performance.

Income Statement

The company's income statement indicates significant challenges, with substantial negative net income and EBIT margins over recent years. Although there was a positive revenue figure in 2023, the revenue growth has been erratic, with a substantial decline from 2020 to 2022 followed by a modest recovery. Gross profit margins have been inconsistent, which, coupled with negative net profit and EBIT margins, underscores profitability issues.

Balance Sheet

The balance sheet shows a strong equity base relative to liabilities, with a debt-to-equity ratio remaining low due to minimal debt levels. However, the equity ratio has been declining, indicating diminishing equity relative to total assets. The company maintains a significant cash position, which is a positive sign of liquidity.

Cash Flow

Cash flow analysis reveals persistent negative free cash flows, indicating challenges in generating sufficient cash from operations. The absence of operating cash flow data for 2023 makes it difficult to assess the recent cash generation ability. Historical trends show negative operating cash flow, impacting the overall cash flow position negatively.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
27.64M	-221.56M	88.03M	1.54B	30.00M
	Gross Profit
27.64M	-248.80M	41.59M	1.54B	30.00M
	EBIT
-1.24B	-1.97B	-2.07B	155.57M	-1.46B
	EBITDA
-1.21B	-1.94B	-2.06B	168.31M	-1.46B
	Net Income Common Stockholders
-1.47B	-2.51B	-2.33B	470.92M	-1.49B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.29B	3.45B	4.28B	4.79B	1.17B
	Total Assets
2.61B	4.07B	5.63B	6.33B	1.74B
	Total Debt
18.89M	74.99M	112.45M	13.60M	132.50M
	Net Debt
-2.01B	-3.14B	-3.41B	-4.75B	-1.00B
	Total Liabilities
894.81M	1.07B	1.04B	706.65M	3.77B
	Stockholders Equity
1.72B	3.01B	4.59B	5.63B	-2.03B
Cash Flow		Free Cash Flow
-1.32B	-1.15B	-1.00B	425.55M	-880.22M
	Operating Cash Flow
―	-1.10B	-973.09M	433.56M	-867.98M
	Investing Cash Flow
102.52M	458.38M	-727.21M	-201.90M	212.46M
	Financing Cash Flow
7.57M	42.36M	593.92M	3.44B	152.71M

I-MAB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMAB, the sentiment is Negative. The current price of 0.84 is above the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.85, and below the 200-day MA of 1.06, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.67 is Neutral, neither overbought nor oversold. The STOCH value of 37.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMAB.

I-MAB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.35B	3.41	-40.48%	2.89%	17.92%	2.25%
IMAB	45 Neutral	$66.00M	―	-22.38%	―	―	―
ADAG	38 Underperform	$66.90M	―	-55.14%	―	-99.43%	-69.40%
ZURA	38 Underperform	$93.67M	―	-44.03%	―	―	86.65%
ACHV	37 Underperform	$82.55M	―	-409.51%	―	―	19.70%
VOR	33 Underperform	$87.11M	―	-94.52%	―	―	2.98%
CNTX	28 Underperform	$84.32M	―	-49.89%	―	―	65.02%